Browse RARG

Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00104 Ligand-binding domain of nuclear hormone receptor
PF00105 Zinc finger
Function

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. Required for limb bud development. In concert with RARA or RARB, required for skeletal growth, matrix homeostasis and growth plate function (By similarity).

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001501 skeletal system development
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0002062 chondrocyte differentiation
GO:0002063 chondrocyte development
GO:0002064 epithelial cell development
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002066 columnar/cuboidal epithelial cell development
GO:0002067 glandular epithelial cell differentiation
GO:0002068 glandular epithelial cell development
GO:0003002 regionalization
GO:0003406 retinal pigment epithelium development
GO:0003413 chondrocyte differentiation involved in endochondral bone morphogenesis
GO:0003415 chondrocyte hypertrophy
GO:0003416 endochondral bone growth
GO:0003417 growth plate cartilage development
GO:0003418 growth plate cartilage chondrocyte differentiation
GO:0003430 growth plate cartilage chondrocyte growth
GO:0003431 growth plate cartilage chondrocyte development
GO:0003433 chondrocyte development involved in endochondral bone morphogenesis
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0007272 ensheathment of neurons
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0008361 regulation of cell size
GO:0008366 axon ensheathment
GO:0009755 hormone-mediated signaling pathway
GO:0009952 anterior/posterior pattern specification
GO:0014020 primary neural tube formation
GO:0016049 cell growth
GO:0016055 Wnt signaling pathway
GO:0016331 morphogenesis of embryonic epithelium
GO:0021915 neural tube development
GO:0022612 gland morphogenesis
GO:0030099 myeloid cell differentiation
GO:0030326 embryonic limb morphogenesis
GO:0030522 intracellular receptor signaling pathway
GO:0030850 prostate gland development
GO:0031076 embryonic camera-type eye development
GO:0031641 regulation of myelination
GO:0032330 regulation of chondrocyte differentiation
GO:0032331 negative regulation of chondrocyte differentiation
GO:0032526 response to retinoic acid
GO:0032535 regulation of cellular component size
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035116 embryonic hindlimb morphogenesis
GO:0035137 hindlimb morphogenesis
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0035264 multicellular organism growth
GO:0035265 organ growth
GO:0042552 myelination
GO:0043010 camera-type eye development
GO:0043401 steroid hormone mediated signaling pathway
GO:0045637 regulation of myeloid cell differentiation
GO:0048048 embryonic eye morphogenesis
GO:0048384 retinoic acid receptor signaling pathway
GO:0048545 response to steroid hormone
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048588 developmental cell growth
GO:0048592 eye morphogenesis
GO:0048608 reproductive structure development
GO:0048705 skeletal system morphogenesis
GO:0048732 gland development
GO:0048736 appendage development
GO:0051216 cartilage development
GO:0060041 retina development in camera-type eye
GO:0060070 canonical Wnt signaling pathway
GO:0060173 limb development
GO:0060324 face development
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060350 endochondral bone morphogenesis
GO:0060351 cartilage development involved in endochondral bone morphogenesis
GO:0060438 trachea development
GO:0060512 prostate gland morphogenesis
GO:0060534 trachea cartilage development
GO:0060541 respiratory system development
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060606 tube closure
GO:0060740 prostate gland epithelium morphogenesis
GO:0061035 regulation of cartilage development
GO:0061037 negative regulation of cartilage development
GO:0061448 connective tissue development
GO:0061458 reproductive system development
GO:0070384 Harderian gland development
GO:0071229 cellular response to acid chemical
GO:0071300 cellular response to retinoic acid
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0072175 epithelial tube formation
GO:0090066 regulation of anatomical structure size
GO:0090596 sensory organ morphogenesis
GO:0098868 bone growth
GO:0198738 cell-cell signaling by wnt
GO:1903706 regulation of hemopoiesis
Molecular Function GO:0003707 steroid hormone receptor activity
GO:0003708 retinoic acid receptor activity
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding
GO:0008134 transcription factor binding
GO:0035257 nuclear hormone receptor binding
GO:0042974 retinoic acid receptor binding
GO:0046965 retinoid X receptor binding
GO:0051427 hormone receptor binding
GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0005667 transcription factor complex
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-1266738: Developmental Biology
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-383280: Nuclear Receptor transcription pathway
R-HSA-162582: Signal Transduction
R-HSA-5362517: Signaling by Retinoic Acid
Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RARG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RARG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RARG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0110.974
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6230.747
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4760.733
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3720.464
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2820.883
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4840.839
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1730.669
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5690.7
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.30.851
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7580.575
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0210.261
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0050.969
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RARG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RARG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RARG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RARG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RARG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RARG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RARG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRARG
Nameretinoic acid receptor, gamma
Aliases RARC; NR1B3; RAR-gamma; nuclear receptor subfamily 1 group B member 3; retinoic acid nuclear receptor gamma ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RARG collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting RARG.
ID Name Drug Type Targets #Targets
DB00210AdapaleneSmall MoleculeRARA, RARB, RARG, RXRA, RXRB, RXRG6
DB00459AcitretinSmall MoleculeRARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG7
DB00523AlitretinoinSmall MoleculeCYP26C1, IGFBP3, PSG5, RARA, RARB, RARG, RXRA, RXRB, RXRG9
DB00755TretinoinSmall MoleculeALDH1A1, ALDH1A2, CYP26A1, CYP26B1, CYP26C1, GPRC5A, HPGDS, LCN1, ......19
DB00799TazaroteneSmall MoleculeRARA, RARB, RARG, RXRB4
DB00926EtretinateSmall MoleculeRARA, RARB, RARG, RXRA, RXRB, RXRG6
DB02258SR11254Small MoleculeRARG1
DB024664-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic AcidSmall MoleculeRARG1
DB02741CD564Small MoleculeRARG1
DB03279Dodecyl-Alpha-D-MaltosideSmall MoleculeRARG1
DB03466BMS184394Small MoleculeRARG1
DB05467R667Small MoleculeRARG1
DB05785LGD-1550Small MoleculeJUN, RARA, RARB, RARG4
DB070313-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acidSmall MoleculeRARG1
DB072943-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acidSmall MoleculeRARG1